Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Pam Van Ry"'
Autor:
Ryan D. Wuebbles, Vivian Cruz, Pam Van Ry, Pamela Barraza-Flores, Paul D. Brewer, Peter Jones, Dean J. Burkin
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 13, Iss , Pp 145-153 (2019)
Duchenne muscular dystrophy (DMD) is a devastating disease caused by mutations in the dystrophin gene that result in the complete absence of dystrophin protein. We have shown previously that recombinant mouse Galectin-1 treatment improves physiologic
Externí odkaz:
https://doaj.org/article/7cb9207feebe46a59941dbb479c9bbe1
Publikováno v:
Physiology. 38
The receptor for advanced glycation end products (RAGE) is a key contributor to the immune and inflammatory response in a myriad of diseases. RAGE is a transmembrane pattern recognition receptor with special interest in pulmonary anomalies due to its
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7d958c60aa260c6688f41a7ee0ca094a
https://doi.org/10.1152/physiol.2023.38.s1.5733440
https://doi.org/10.1152/physiol.2023.38.s1.5733440
Autor:
Braden Kartchner, Jonathan Spallino, Luke Westhoff, Ethan Durham, Parker Nelson, Colton Hansen, Pam Van Ry
Publikováno v:
Physiology. 38
Limb-girdle muscular dystrophy type 2B (LGMD2B) is a devastating autosomal recessive disease for which there are no current FDA-approved treatments. Our previous research shows that short-term recombinant human Galectin-1 (rHsGal-1) treatment is effe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fea6fa737cd5781e0e8a11b6cbcb3f0d
https://doi.org/10.1152/physiol.2023.38.s1.5730571
https://doi.org/10.1152/physiol.2023.38.s1.5730571
Autor:
Pam Van Ry, Ryan D. Wuebbles, Pamela Barraza-Flores, Peter L. Jones, Vivian Cruz, Dean J. Burkin, Paul Duffield Brewer
Publikováno v:
Molecular Therapy. Methods & Clinical Development
Molecular Therapy: Methods & Clinical Development, Vol 13, Iss, Pp 145-153 (2019)
Molecular Therapy: Methods & Clinical Development, Vol 13, Iss, Pp 145-153 (2019)
Duchenne muscular dystrophy (DMD) is a devastating disease caused by mutations in the dystrophin gene that result in the complete absence of dystrophin protein. We have shown previously that recombinant mouse Galectin-1 treatment improves physiologic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::16c091173d1192e19c88b532c935251e
http://europepmc.org/articles/PMC6369265
http://europepmc.org/articles/PMC6369265